iBio, Inc. Common Stock (IBIO) - Total Liabilities
Based on the latest financial reports, iBio, Inc. Common Stock (IBIO) has total liabilities worth $7.83 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore iBio, Inc. Common Stock equity growth rate to track the company's year-over-year net asset growth rate.
iBio, Inc. Common Stock - Total Liabilities Trend (2007–2025)
This chart illustrates how iBio, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
iBio, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of iBio, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nila Spaces Limited
NSE:NILASPACES
|
India | Rs1.94 Billion |
|
SRM Entertainment, Inc. Common Stock
NASDAQ:SRM
|
USA | $751.58K |
|
SuperCom Ltd
F:50S
|
Germany | €28.23 Million |
|
Dinamik Isi Makina Yalitim Malzemeleri Sanayi ve Ticaret AS
IS:DNISI
|
Turkey | TL343.85 Million |
|
Polychem Indonesia Tbk
JK:ADMG
|
Indonesia | Rp44.23 Million |
|
Klotho Neurosciences, Inc.
NASDAQ:KLTO
|
USA | $145.89K |
|
Poujoulat S.A.
PA:ALPJT
|
France | €215.04 Million |
|
Optivision Technology
TWO:3666
|
Taiwan | NT$387.67 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down iBio, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see iBio, Inc. Common Stock market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how iBio, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for iBio, Inc. Common Stock (2007–2025)
The table below shows the annual total liabilities of iBio, Inc. Common Stock from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $8.30 Million | +12.08% |
| 2024-06-30 | $7.41 Million | -71.31% |
| 2023-06-30 | $25.83 Million | -28.10% |
| 2022-06-30 | $35.92 Million | -6.46% |
| 2021-06-30 | $38.40 Million | +2.18% |
| 2020-06-30 | $37.58 Million | +33.61% |
| 2019-06-30 | $28.13 Million | +4.49% |
| 2018-06-30 | $26.92 Million | -0.65% |
| 2017-06-30 | $27.09 Million | -1.67% |
| 2016-06-30 | $27.56 Million | +2081.79% |
| 2015-06-30 | $1.26 Million | +219.75% |
| 2014-06-30 | $395.00K | -90.78% |
| 2013-06-30 | $4.29 Million | +19.20% |
| 2012-06-30 | $3.60 Million | -49.64% |
| 2011-06-30 | $7.14 Million | +85.24% |
| 2010-06-30 | $3.85 Million | +610.91% |
| 2009-06-30 | $542.14K | -94.44% |
| 2008-06-30 | $9.75 Million | +20.37% |
| 2007-06-30 | $8.10 Million | -- |
About iBio, Inc. Common Stock
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu,… Read more